ArticlePloS one2013
Gleevec, an Abl family inhibitor, produces a profound change in cell shape and migration.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Frontiers in cell and developmental biology · 2025Article
- Depletion of Arg/Abl2 improves endothelial cell adhesion and prevents vascular leak during inflammation.Angiogenesis · 2021Article
- Comparative mapping of crawling-cell morphodynamics in deep learning-based feature space.PLoS computational biology · 2021Article
- Rotation of stress fibers as a single wheel in migrating fish keratocytes.Scientific reports · 2018Article
- The Role of Stress Fibers in the Shape Determination Mechanism of Fish Keratocytes.Biophysical journal · 2016Article
- The molecular dynamics of crawling migration in microtubule-disrupted keratocytes.Biophysics and physicobiology · 2015Article
- Vinculin phosphorylation differentially regulates mechanotransduction at cell-cell and cell-matrix adhesions.The Journal of cell biology · 2014Article
- Nanograting structure promotes lamellipodia-based cell collective migration and wound healing.Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2014Article
- Defying c-Abl signaling circuits through small allosteric compounds.Frontiers in genetics · 2014Article
- The Focal Adhesion Analysis Server: a web tool for analyzing focal adhesion dynamics.F1000Research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
The issue of how contractility and adhesion are related to cell shape and migration pattern remains largely unresolved. In this paper we report that Gleevec (Imatinib), an Abl family kinase inhibitor, produces a profound change in the shape and migration of rat bladder tumor cells (NBTII) plated on collagen-coated substrates. Cells treated with Gleevec adopt a highly spread D-shape and migrate more rapidly with greater persistence. Accompanying this more spread state is an increase in integrin-mediated adhesion coupled with increases in the size and number of discrete adhesions. In addition, both total internal reflection fluorescence microscopy (TIRFM) and interference reflection microscopy (IRM) revealed a band of small punctate adhesions with rapid turnover near the cell leading margin. These changes led to an increase in global cell-substrate adhesion strength, as assessed by laminar flow experiments. Gleevec-treated cells have greater RhoA activity which, via myosin activation, led to an increase in the magnitude of total traction force applied to the substrate. These chemical and physical alterations upon Gleevec treatment produce the dramatic change in morphology and migration that is observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.